Overview

A Study of CT-388 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-02-21

Target enrollment:

Participant gender:

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants with obesity or who are overweight with at least one weight-related comorbidity.

Phase:

PHASE2

Details

Lead Sponsor:

Carmot Therapeutics, Inc.

Collaborator:

Hoffmann-La Roche